Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Late cornified envelope protein 1C (LCE1C) is a human protein encoded by the LCE1C gene, part of the late cornified envelope cluster on chromosome 1q21[3][7]. It serves as a precursor to the cornified envelope of the stratum corneum, contributing to the barrier function of the epidermis[2][3][7]. The protein is implicated in keratinization—a process vital for skin formation and integrity[3]. LCE1C is a transcriptional target downstream of p63, particularly regulated by phosphorylation of TAp63, and it plays a role in epithelial differentiation, cell cycle regulation, and acts as a tumor suppressor by interacting with and translocating PRMT5 from the nucleus to the cytoplasm, reducing PRMT5 nuclear function[1][5][6]. Diseases associated with variants in LCE1C include psoriasis and certain cataracts[3]. There are currently no drugs or therapies directly known to target LCE1C.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Late cornified envelope protein 1C (LCE1C).